- Bestsellers
- Alcoholism
- COVID-19
- Allergy
- Anti Fungal
- Alzheimers
- Anti Viral
- Anti-Depressants
- Anti-Inflammatory
- Antibacterial
- Antiparasitic
- Antibiotics
- Arthritis
- Asthma
- Birth Control
- Blood Pressure
- Cancer
- Cardiovascular
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Drop
- Gastro Health
- General Health
- Hair Loss
- Hepatitis C Virus (HCV)
- HIV
- Hormones
- Men's ED Packs
- Men's Health
- Mental Illness
- Motion Sickness
- Muscle Relaxant
- Pain Relief
- Parkinson’s Disease
- Veterinary Medicines
- Quit Smoking
- Vitamins
- Skin Care
- Sleeping Aids
- Weight Loss
- Women's Health
Yasmin ( Drospirenone / Ethinyl Estradiol )
Yasmin (drospirenone and ethinyl estradiol) is a combined oral contraceptive indicated for the prevention of pregnancy in women of reproductive age. It contains the progestin drospirenone, which has antimineralocorticoid properties resembling those of natural progesterone, and the estrogen ethinyl estradiol. Yasmin works primarily by suppressing ovulation through inhibition of gonadotropin release; additionally, it thickens cervical mucus to impede sperm penetration and alters the endometrium to reduce the likelihood of implantation. It is also approved for the treatment of moderate acne vulgaris and premenstrual dysphoric disorder (PMDD) in women who also desire oral contraception.
Usual adult dose: One active tablet (3 mg drospirenone and 0.03 mg ethinyl estradiol) taken orally once daily at the same time every day for 21 consecutive days, followed by a 7‑day hormone‑free interval during which a withdrawal bleed usually occurs. The next 21‑day cycle is started on the day after the tablet‑free interval, regardless of whether bleeding has stopped. For first‑time users, the initial tablet should be taken on the first day of the menstrual cycle (Day 1 start); contraceptive protection is immediate. If starting on any other day, a backup non‑hormonal method of contraception must be used for the first 7 days. Missed‑pill instructions vary depending on the delay; generally, if one active tablet is missed by less than 24 hours, it should be taken as soon as remembered and the next tablet at the usual time. If missed by more than 24 hours, contraceptive protection may be reduced and backup contraception is required. Yasmin may also be used in an extended or continuous regimen as directed by a healthcare professional.
Dosage form: Film‑coated tablets: each active tablet contains 3 mg drospirenone and 0.03 mg ethinyl estradiol. The 21‑day blister pack contains 21 active, light‑pink, round tablets; some packs also include 7 inert white placebo tablets (28‑day pack) to aid adherence.
Onset of action: Contraceptive efficacy is achieved immediately when starting on the first day of the menstrual cycle. When starting on any other day, ovulation suppression and reliable protection are established after 7 consecutive days of active tablet intake.
Duration of action: Each daily dose provides 24‑hour suppression of ovulation. Consistent daily use maintains contraceptive protection; the 7‑day hormone‑free interval must not exceed 7 days to ensure continued ovarian suppression.
Alcohol recommendation: There is no direct drug interaction between combined oral contraceptives and alcohol. However, excessive alcohol consumption can lead to vomiting within 3 to 4 hours of tablet ingestion, potentially compromising contraceptive reliability. Alcohol may also increase blood pressure, which is particularly relevant with drospirenone‑containing products due to the mild potassium‑sparing diuretic effect; patients with hypertension or renal impairment should exercise caution. Moderate alcohol intake does not appear to affect contraceptive efficacy.
Most common side effects: Headache, nausea, breast tenderness, mood changes, breakthrough bleeding/spotting, and unscheduled uterine bleeding. These are most common during the first three cycles and often resolve with continued use. Drospirenone has antimineralocorticoid activity, which may cause mild potassium retention; therefore, serum potassium levels should be monitored in patients taking other drugs that increase potassium (e.g., NSAIDs, ACE inhibitors, potassium‑sparing diuretics) and in those with renal impairment. Combined hormonal contraceptives are associated with an increased risk of venous thromboembolism (VTE), arterial thromboembolism, hypertension, and, rarely, hepatic adenoma. The risk of VTE is higher in women over 35, smokers, those with obesity, and those with a personal or family history of thrombosis. Yasmin should not be used in women with a history of VTE, cerebrovascular or coronary artery disease, liver disease, uncontrolled hypertension, diabetes with vascular complications, or known or suspected breast cancer. Smoking increases the risk of serious cardiovascular events; women using Yasmin should not smoke.
Would you like to try Yasmin (Drospirenone / Ethinyl Estradiol) without a prescription?
+ Next orders 10% discount
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
